Zobrazeno 1 - 10
of 552
pro vyhledávání: ''
Autor:
Ryohei Yoshida, Maria Saigi, Tetsuo Tani, Benjamin F. Springer, Hirofumi Shibata, Shunsuke Kitajima, Navin R. Mahadevan, Marco Campisi, William Kim, Yoshihisa Kobayashi, Tran C. Thai, Koji Haratani, Yurie Yamamoto, Shriram K. Sundararaman, Erik H. Knelson, Amir Vajdi, Israel Canadas, Ravindra Uppaluri, Cloud P. Paweletz, Juan J. Miret, Patrick H. Lizotte, Prafulla C. Gokhale, Pasi A. Jänne, David A. Barbie
Publikováno v:
Cancer Res
Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been unsuccessful to date. Here, we discover that MET amplification, the most common mechanism
Autor:
James Sinnett-Smith, Tarique Anwar, Elaine F. Reed, Yaroslav Teper, Guido Eibl, Enrique Rozengurt
Publikováno v:
Molecular Cancer Therapeutics. 21:1652-1662
Pancreatic ductal adenocarcinoma (PDAC) remains an aggressive disease that is expected to become the second cause of cancer fatalities during the next decade. As therapeutic options are limited, novel targets, and agents for therapeutic intervention
Autor:
Haoyan Li, Yin Wang, Kevin Lin, Varadha Balaji Venkadakrishnan, Martin Bakht, Wei Shi, Chenling Meng, Jie Zhang, Kaitlyn Tremble, Xin Liang, Jian H. Song, Xu Feng, Vivien Van, Pingna Deng, Jared K. Burks, Ana Aparicio, Khandan Keyomarsi, Junjie Chen, Yue Lu, Himisha Beltran, Di Zhao
Publikováno v:
Cancer Res
Clinical studies have shown that subsets of patients with cancer achieve a significant benefit from Aurora kinase inhibitors, suggesting an urgent need to identify biomarkers for predicting drug response. Chromodomain helicase DNA binding protein 1 (
Autor:
Astrid Zimmermann, Frank T. Zenke, Li-Ya Chiu, Heike Dahmen, Ulrich Pehl, Thomas Fuchss, Thomas Grombacher, Beatrix Blume, Lyubomir T. Vassilev, Andree Blaukat
Publikováno v:
Molecular Cancer Therapeutics. 21:859-870
Radiotherapy and chemical DNA-damaging agents are among the most widely used classes of cancer therapeutics today. Double-strand breaks (DSB) induced by many of these treatments are lethal to cancer cells if left unrepaired. Ataxia telangiectasia-mut
Autor:
Kosuke Yoshida, Akira Yokoi, Tomofumi Yamamoto, Yusuke Hayashi, Jun Nakayama, Tsuyoshi Yokoi, Hiroshi Yoshida, Tomoyasu Kato, Hiroaki Kajiyama, Yusuke Yamamoto
Publikováno v:
Clinical Cancer Research. 28:2147-2159
Purpose: Uterine leiomyosarcoma is among the most aggressive gynecological malignancies. No effective treatment strategies have been established. This study aimed to identify novel therapeutic targets for uterine leiomyosarcoma based on transcriptome
Autor:
Zena Wilson, Rajesh Odedra, Yann Wallez, Paul W.G. Wijnhoven, Adina M. Hughes, Joe Gerrard, Gemma N. Jones, Hannah Bargh-Dawson, Elaine Brown, Lucy A. Young, Mark J. O'Connor, Alan Lau
Publikováno v:
Cancer Research. 82:1140-1152
AZD6738 (ceralasertib) is a potent and selective orally bioavailable inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase. ATR is activated in response to stalled DNA replication forks to promote G2–M cell-cycle checkpoints and fork res
Autor:
Alessia Anastasia, Giulia Dellavedova, Antonio Ramos-Montoya, Neil James, Giovanna Chiorino, Massimo Russo, Hana Baakza, Joanne Wilson, Carmen Ghilardi, Elaine B. Cadogan, Raffaella Giavazzi, Maria Rosa Bani
Publikováno v:
Molecular Cancer Therapeutics. 21:555-567
Ovarian cancer is the deadliest gynecologic cancer, with a 5-year survival rate of 30%, when the disease has spread throughout the peritoneal cavity. We investigated the efficacy to delay disease progression by the DNA-dependent protein kinase (DNA-P
Autor:
Magda Bahcall, Luke J. Taus, Taebo Sim, Prafulla C. Gokhale, Jens Köhler, Stephen Wang, Nam Doo Kim, Cloud P. Paweletz, Zihan Wei, Yanan Kuang, Christie J. Lau, Pasi A. Jänne, Pratik R Chopade, Kshiti Dholakia, Sujuan Guo, Fangxin Hong, Jiannan Guo, Paul Kirschmeier
Publikováno v:
Mol Cancer Ther
MET-targeted therapies are clinically effective in MET-amplified and MET exon 14 deletion mutant (METex14) non–small cell lung cancers (NSCLCs), but their efficacy is limited by the development of drug resistance. Structurally distinct MET tyrosine
Autor:
Emanuela, Dylgjeri, Karen E, Knudsen
Publikováno v:
Cancer Research. 82:523-533
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a pleiotropic protein kinase that plays critical roles in cellular processes fundamental to cancer. DNA-PKcs expression and activity are frequently deregulated in multiple hematologic and s
Autor:
Kristyna Kupcova, Joanna Barankiewicz, Bjoern Chapuy, Anna Szumera-Ciećkiewicz, Anna Polak, Magdalena Winiarska, Joanna Domagala, Dorota Komar, Bartosz Pula, Magdalena Cybulska, Agnieszka Graczyk-Jarzynka, Ewa Jabłońska, Dominika Nowis, Michal Mikula, Michael R. Green, Krzysztof Brzózka, Michał Pawlak, Beata Pyrzynska, Filip Garbicz, Andrea Massimiliano Tomirotti, Malgorzata Statkiewicz, Monika Prochorec-Sobieszek, Kamil Bojarczuk, Aniela Golas, Ondrej Havranek, Jakub Golab, Marta Gajewska, Patryk Górniak, Maciej Szydlowski, Mariana Pacheco-Blanco, Emilia Bialopiotrowicz, Grzegorz Rymkiewicz, Przemyslaw Juszczynski
Publikováno v:
Cancer Research. 81:6029-6043
The family of PIM serine/threonine kinases includes three highly conserved oncogenes, PIM1, PIM2, and PIM3, which regulate multiple prosurvival pathways and cooperate with other oncogenes such as MYC. Recent genomic CRISPR-Cas9 screens further highli